Albireo Pharma Valuation
Is ALBO * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ALBO * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ALBO *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ALBO *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALBO *?
Other financial metrics that can be useful for relative valuation.
What is ALBO *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$921.13m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 12.3x |
Enterprise Value/EBITDA | -5.8x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ALBO *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 16.3x | ||
6855 Ascentage Pharma Group International | 32.8x | 35.0% | HK$7.8b |
LAB B Genomma Lab Internacional. de | 1x | 8.2% | Mex$16.3b |
ARCT Arcturus Therapeutics Holdings | 5.3x | 37.6% | US$707.5m |
2162 Keymed Biosciences | 26.1x | 37.1% | HK$9.5b |
ALBO * Albireo Pharma | 16.1x | 51.1% | Mex$921.1m |
Price-To-Sales vs Peers: ALBO * is good value based on its Price-To-Sales Ratio (16.1x) compared to the peer average (19x).
Price to Earnings Ratio vs Industry
How does ALBO *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Sales vs Industry: ALBO * is expensive based on its Price-To-Sales Ratio (16.1x) compared to the Global Biotechs industry average (9.6x).
Price to Sales Ratio vs Fair Ratio
What is ALBO *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 16.1x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ALBO *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.